tiprankstipranks
Advertisement
Advertisement

Tristel Non-Executive Director Increases Stake in Infection Prevention Group

Story Highlights
  • Tristel’s Non-Executive Director Caroline Stephens bought 2,597 shares, lifting her holding to 6,878.
  • The director’s modest stake increase signals board confidence closely watched by Tristel investors.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Tristel Non-Executive Director Increases Stake in Infection Prevention Group

Claim 55% Off TipRanks

An update from Tristel ( (GB:TSTL) ) is now available.

Tristel plc, the AIM-listed infection prevention specialist, has disclosed that Non-Executive Director Caroline Stephens has increased her stake in the company with the purchase of 2,597 ordinary shares at 382.47 pence each. Following this transaction on 20 March 2026, Stephens now holds 6,878 shares, representing roughly 0.014% of Tristel’s issued share capital, a modest but positive signal of board-level confidence in the business.

The share purchase, executed on the London Stock Exchange’s AIM market, underscores insider alignment with Tristel’s strategic ambitions in the global infection prevention sector. While the holding remains small in percentage terms, such director dealings are closely watched by investors as indicators of sentiment toward the company’s growth prospects and operational momentum.

The most recent analyst rating on (GB:TSTL) stock is a Hold with a £421.00 price target. To see the full list of analyst forecasts on Tristel stock, see the GB:TSTL Stock Forecast page.

Spark’s Take on TSTL Stock

According to Spark, TipRanks’ AI Analyst, TSTL is a Outperform.

The score is driven primarily by strong financial performance and a constructive earnings update with reiterated growth/margin targets and solid H1 results. Offsetting factors are weak near-term technical momentum (below key moving averages with negative MACD) and a relatively high P/E, partially balanced by the ~3.6% dividend yield.

To see Spark’s full report on TSTL stock, click here.

More about Tristel

Tristel plc is a global infection prevention company that manufactures and supplies products based on its proprietary chlorine dioxide chemistry, focusing on manual decontamination of medical devices and sporicidal surface disinfection. Headquartered near Cambridge, it operates through 16 subsidiaries in over 40 countries, employs about 270 people, and has been listed on AIM since 2005 with targets of double-digit revenue growth and strong margins.

Average Trading Volume: 133,833

Technical Sentiment Signal: Buy

Current Market Cap: £182.1M

For an in-depth examination of TSTL stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1